Methisazone therapy in pediatric vaccinia complications.

Methisazone 40 mg/kg/day was administered orally to six pediatric and one adult patient who contracted vesicular complications affecting the skin or mucocutaneous junctions 3 to 9 days after antismallpox vaccination, and to one elderly man with myeloid leukemia who developed vaccinia necrosum. Therapy was commenced 2 to 10 days after onset of complications and was administered for 3 days. All patients with skin or mucocutaneous complications showed dramatic clinical responses within one day after commencement of antiviral chemotherapy, and complete recovery occurred within one week. Clinical improvement was noted 4 days after therapy was begun in the case of vaccinia necrosum, and recovery occurred after 3 weeks.
AuthorsD M McLean
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 284 Pg. 118-21 (Mar 4 1977) ISSN: 0077-8923 [Print] UNITED STATES
PMID280134 (Publication Type: Journal Article)
Chemical References
  • Thiosemicarbazones
  • Methisazone
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Methisazone (therapeutic use)
  • Necrosis
  • Skin Diseases, Infectious (drug therapy, pathology)
  • Thiosemicarbazones (therapeutic use)
  • Vaccinia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: